An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients

Canadian Journal of Psychiatry

Volumn 54, Issue 4, 2009, Pages 269-274

  Kisely, Stephen ^a,b   Cox, Martha ^a   Campbell, Leslie Anne ^c   Cooke, Charmaine ^d   Gardner, David ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Capital District Health Authority   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Obesity; Psychotropics; Seniors

Indexed keywords

AMITRIPTYLINE; LITHIUM; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GERIATRIC PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MENTAL PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE; RISK ASSESSMENT; SCHIZOPHRENIA;

EID: 65349166665     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370905400408     Document Type: Article

References (27)

1. Trakas K, Lawrence K, Shear NH. Utilization of health care resources by obese Canadians. CMAJ. 1999;160:1457-1462.
2. KatzmarzykP. The Canadian obesity epidemic: 1995-1998. CMAJ. 2002;166:1039-1040.
3. Torrance GM, Hooper MD, Reeder BA. Trends in overweight and obesity among adults in Canada (1970-1992): evidence from national surveys using measured height and weight. Int J Obes Relat Metab Disord. 2002;26:797-804.
4. Spurgeon D. Childhood obesity in Canada has tripled in past 20 years. BMJ. 2002;324:1416.
5. Kulkarni SK, Kaur G. Pharmacodynamics of drug-induced weight gain. Drugs Today (Barc). 2001;37:559-571.
6. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101:277-288.
7. Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv. 2002;53:842-847.
8. Schwartz T, Nihalani M, Jindal S, et al Psychiatric medication-induced obesity: a review. Obesity Rev. 2004;5:115-121.
9. IMS Health. Academic reference manual. Montreal (QC): IMS Health Canada; 2002.
10. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480-491.
11. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
12. Lage MJ, Kemner JE. Use of a typical antipsychotics and the incidence of diabetes: evidence from a claims database. Schizophr Res. 2002;53(Suppl 1):S166.
13. Cunningham F, Lambert B, Dalack G, et al. Diabetes associated with antipsychotic use in veterans with schizophrenia. Pharmacoepidemiol Drug Saf. 2003;12(Suppl 1):S154-S155.
14. Carlson C, Hornbuckle K, DeLisle F, et al. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur Neuropsychopharmacol. 2006;16:366-375.
15. Alexopoulos GS, Streim J, Carpenter D, et al. Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65(Suppl 2):5-99.
16. Gareri P, De Fazio P, De Fazio S, et al. Adverse effects ofatypical antipsychotics in the elderly: a review. Drugs Aging. 2006;23:937-956.
17. Population Health Research Unit. Research data repository [Internet]. Halifax (NS): Dalhousie University; 2009 [cited 2009 Jan 21]. Available from: http://metadata.phru.dal.ca.
18. Davis JM. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry. 1976;33:858-861.
19. Humberstone V, Wheeler A, Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry. 2004;38:240-245.
20. Gilbert C. Mental health surveillance. Proceedings ofthe Mental Health Research Showcase, 2006 Oct 30-Nov 1, Banff (AB) [Internet]. Edmonton (AB): Mental Health Board; 2006 [cited 2007 Dec 20]. Available from: http://www.buksa.com/showcase/docs/020D-Gilbert.pdf.
21. Gilbert C, Jones W, Schopflocher D, et al. Use of Provincial Administrative Data for Surveillance of Mental Disorders, Feasibility Study. Ottawa (ON): Surveillance Division, Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada; 2007.
22. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050-1060.
23. Zipursky RB, GuH, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543.
24. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903-912.
25. Chan JCN, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf. 1996;15:135-157.
26. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920-930.
27. Caro JJ, Ward A, Levinton C, et al. The risk ofdiabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135-1139.